Effect of Psyllium (Plantago Ovata) on Digestive Disorders in Familial Amyloidosis (Psyllium)

  • STATUS
    Recruiting
  • End date
    Mar 1, 2024
  • participants needed
    20
  • sponsor
    Centre Hospitalier Universitaire de Nice
Updated on 25 July 2022

Summary

Familial amyloidosis is a rare disease that mainly affects the nerves and heart, but also more rarely the eyes and kidneys. This disease is due to a mutation in the gene encoding the synthesis of transthyretin, resulting in a modification of the translated protein. This abnormal protein and its derivatives are deposited in the form of a toxic "amyloid" substance in tissues and organs, altering their functions, particularly in the gastrointestinal tract.

From a gastrointestinal perspective, different treatments can be proposed in the absence of specific recommendations for familial amyloidosis. The hygienic and dietary measures consist of avoiding tobacco, alcohol and carbonated drinks, limiting fatty meals rich in poorly digestible fibers, and splitting meals. If this fails, metoclopramide and domperidone are suggested. As a second-line erythromycin, can be used with caution because of cardiac risks and drug interactions. Polyethylene glycol-based osmotic laxatives can be used to treat constipation. Alternating diarrhea and constipation can be treated with ispaghul-based laxatives, aiming at transit regulation. Finally, refractory diarrhea can be treated with the administration of loperamide. If this fails, treatment with a somatostatin analogue may be offered.

However, all these treatments can present significant side effects, therefore natural alternatives are often sought. Psyllium in particular regulates transit by normalizing stool consistency: it is effective against digestive disorders such as constipation, but it is also effective in the event of diarrhea. It allows the formation of a viscous gel by the hydrophilicity of polysaccharides macromolecules, increasing the fecal bowl which stimulates peristalsis and facilitates defecation. The WHO has recognized that Psyllium is superior to wheat bran in the treatment of irritable bowel syndrome.

The main objective of the study is to assess the effect of daily Psyllium administration on digestive quality of life in familial amyloidosis patients who suffer from digestive disorders.

Details
Condition Familial Amyloidosis
Treatment Psyllium
Clinical Study IdentifierNCT04695340
SponsorCentre Hospitalier Universitaire de Nice
Last Modified on25 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

male or female age ≥ 18
suffering from familial amyloidosis confirmed by: i) the presence of a specific mutation in transthytetin gene and/or ii) amyloid deposits immunostained for transthyretin in a tissue biopsy
stage 1 or 2 on the familial amyloid polyneuropathy scale
receiving a stable dose for at least 3 months if treated with Patisaran® and inotersen (Tegsedi®)
suffering from gastro intestinal pain ≥ 4 on Visual Analog Scoale (VSA)
affiliated to social security
able to understand the inform consent form
if women of child bearing age, using an effective birth control method for the period of study participation

Exclusion Criteria

allergic to Psyllium
intestinal or esophageal stenosis or any other type of real or suspected gastrointestinal obstruction
protection by law under guardianship, or who cannot participate in a clinical study under Article L. 1121-16 of the French Code of Public Health
participation in the last 3 months in a clinical research study in which he / she has been exposed to a pharmaceutical product or a medical device
treatment with tafamidis (Vyndaqel®)
concomitant intake of food supplements containing zinc, iron, calcium, magnesium or vitamin B12
contraindication to taking Psyllium, e.g. fecal impaction, gastrointestinal obstruction, esophageal or intestinal stenosis or dysphagia to liquids
stage 0 or 3 on the familial amyloid polyneuropathy scale
pregnant or breastfeeding female patient (a urine pregnancy test will be performed for women of childbearing age)
any pathology or concomitant treatment that may interfere with the progress of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note